ArticleClinical & translational immunology2021
High expression of CD38 and MHC class II on CD8
Article in Clinical & translational immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Type I interferon drives dysfunction of a distinct CD8+ HLA-DRB1+ T cell subset in systemic lupus erythematosus.medRxiv : the preprint server for health sciences · 2026Article
- High expression of interleukin-18 receptor alpha correlates with severe respiratory viral disease and defines T cells with reduced cytotoxic signatures.Nature communications · 2025Article
- Cytotoxic T-cell activation profile in critically ill children with malignancies and hemophagocytic lymphohistiocytosis.Pediatric research · 2025Article
- IL-15-Activated CD38Scientific reports · 2025Article
- Simultaneous coinfection with influenza virus and an arbovirus impedes influenza-specific but not Semliki Forest virus-specific responses.Immunology and cell biology · 2025Article
- Prior influenza virus infection alleviates an arbovirus encephalitis by reducing viral titer, inflammation, and cellular infiltrates in the central nervous system.Journal of virology · 2025Article
- Association of CD8BMC cancer · 2024Article
- Prior infection with unrelated neurotropic virus exacerbates influenza disease and impairs lung T cell responses.Nature communications · 2024Article
- Autoimmunity-associated allele of tyrosine phosphatase gene PTPN22 enhances anti-viral immunity.PLoS pathogens · 2024Article
- IL-15-induced CD38Clinical & translational immunology · 2024Article
- Severe respiratory viral infections: T-cell functions diverging from immunity to inflammation.Trends in microbiology · 2023Review
- Tracking the clonal dynamics of SARS-CoV-2-specific T cells in children and adults with mild/asymptomatic COVID-19.Clinical immunology (Orlando, Fla.) · 2023Article
- Broad spectrum SARS-CoV-2-specific immunity in hospitalized First Nations peoples recovering from COVID-19.Immunology and cell biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesAlthough co-expression of CD38 and HLA-DR reflects T-cell activation during viral infections, high and prolonged CD38
methodsWe used mouse models of influenza A/H9N2, A/H7N9 and A/H3N2 infection to investigate mechanisms underpinning CD38
resultsAnalysis of influenza-specific immunodominant D
conclusionsOverall, our study demonstrates that both virus-specific and bystander CD38
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.